Skip to main content
Premium Trial:

Request an Annual Quote

Virginia Commonwealth University to Study Pathwork Dx's Tissue-of-Origin Test

NEW YORK (GenomeWeb News) - Virginia Commonwealth University’s School of Medicine is investigating a tissue-of-origin test made by Pathwork Diagnostics that is designed to help determine the origin of a malignant tumor, the company said today.
 
Pathwork Diagnostics’ Tissue of Origin Test, which uses Affymetrix microarrays and is still in clinical studies, measures 1,600 genes and compares one tissue’s genetic signature against those of other tissue types.
 
There are around 200,000 cancer patients each year in the US who could benefit from a test that can pinpoint the origin of their malignancy.
 
"Such cases are time-consuming for physicians and anxiety-producing for patients, and are a challenge to providing the most appropriate care for the patient,” Catharine Dumur, director of Molecular Morphology Genomics at VCU’s Department of Pathology, said in a statement.
 
“We are eager to see how this investigational new genomics-based test extends and complements traditional histopathological approaches," she added.
 
Financial terms of the agreement were not released.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.